Pfizer reports positive outcomes from trial of mCRC combination therapy
Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for treating metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
The study evaluated the combination against standard chemotherapy, with or without bevacizumab.
During the period of analysis, the combination showed a clinically meaningful and statistically significant improvement in confirmed objective response rate as per blinded independent central review.
Subjects treated with the combination regimen had a median time to respond of 7.1 weeks, with 22.4% experiencing a response lasting a minimum of one year.
In contrast, only 11.4% of subjects on standard chemotherapy achieved a similar duration of response.
Although overall survival (OS) data was not mature, there was a 'promising' trend favouring the combo regimen. The trial is underway for OS and progression-free survival (PFS).
Outcomes of PFS are anticipated this year.
The BREAKWATER trial's safety profile for the combination was consistent with expectations, showing no new safety signals.
Serious treatment-emergent adverse events were slightly higher in the BRAFTOVI group than in the control group.
Pfizer chief oncology officer Roger Dansey said: 'These results of this first analysis were the basis for the first approval of a targeted therapy regimen for use in the first-line setting for patients with metastatic colorectal cancer with a BRAF V600E mutation.
'We are highly encouraged by these response results, which are indicative of the clinically meaningful benefit of BRAFTOVI in reducing tumour size or having no detectable cancer, along with the promising interim analysis of overall survival.'
The US Food and Drug Administration granted accelerated approval to the combination regimen last month, under Project FrontRunner.
Discussions with other regulatory authorities are ongoing to support potential future licence applications for the regimen.
Earlier this month, the company's CREST trial assessing sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in individuals with BCG-naive, high-risk non-muscle invasive bladder cancer, met its primary endpoint.
"Pfizer reports positive outcomes from trial of mCRC combination therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Shifting supply chains, infant formula under scrutiny, lunar mission: Catch up on the day's stories
👋 Welcome to 5 Things PM! The US Food and Drug Administration is conducting the first comprehensive update and review of infant formula since 1998. 'We're going to make American infant formula the gold standard for the world,' Health and Human Services Secretary Robert F. Kennedy Jr. said. Here's what else you might have missed during your busy day: 1️⃣ 'We need to change': With President Donald Trump enacting tariffs on nearly every US import, American companies are scrambling to move their supply chains out of countries like Mexico and China. This small island in the Caribbean could be the answer. 2️⃣ Builders of peace: Congregation Bonai Shalom in Boulder, Colorado, welcomes both Jews and non-Jews to participate in all aspects of the community. An antisemitic attack that injured several members — including a Holocaust survivor — is testing their resilience. 3️⃣ Tracking measles: As cases rise to precipitously high levels in the US, there's a new tool to help measure the spread of the disease. Wastewater surveillance has the potential to identify possible cases days before an individual shows symptoms or seeks care. 4️⃣ Lunar lander: A Japanese company will try to touch down on the moon three months after an uncrewed American spacecraft did the same. Ispace executives said their slow and steady approach offers some long-term advantages. 5️⃣ Candid confession: Kylie Jenner detailed her breast augmentation on TikTok — down to the exact size. Her revelation chips away at a taboo. But is it a victory for transparency or a setback for beauty standards? ☔ Waterlogged: Flash flood emergencies were declared in Wichita and El Dorado, Kansas, after a month's worth of rain fell in one day. The heavy rain flooded roads and submerged cars. • Trump says Putin told him in phone call he will respond to Ukraine's weekend drone attacks• 2 Chinese researchers charged with smuggling biological pathogen to study at university lab• US Education Department threatens Columbia University's accreditation over campus antisemitism concerns 💸 That's how much House Republicans' sweeping tax and spending cuts package would add to the deficit over the next decade, according to a Congressional Budget Office analysis. 🪨 Preserving history: Stephen Townley Bassett is painstakingly recreating mysterious ancient rock art in South Africa before it's lost. His works are no ordinary replicas. 💬 No thanks: Formerly known as 'MAGA Granny,' Hemphill is a convicted January 6 rioter who served two months in federal prison. Watch as she explains why she refused a pardon from President Trump. 🪖 Approximately how many Russian soldiers have been killed or injured in the war with Ukraine? A. 100,000B. 300,000C. 600,000D. 950,000⬇️ Scroll down for the answer. 🎾 C'est magnifique! Heavy underdog Lois Boisson continued her fairy tale run at the French Open tennis tournament by beating No. 6 seed Mirra Andreeva to advance to the semifinals. The hometown hero's next opponent? American Coco Gauff. 👋 We'll see you tomorrow. 🧠 Quiz answer: D. Russia is nearing 1 million war casualties in Ukraine.📧 Check out all of CNN's newsletters. 5 Things PM is produced by CNN's Chris Good, Meghan Pryce, Kimberly Richardson and Morgan Severson.
Yahoo
6 hours ago
- Yahoo
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 4, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks. View original content: SOURCE ERA Congress Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
7 hours ago
- CNN
Shifting supply chains, infant formula under scrutiny, lunar mission: Catch up on the day's stories
👋 Welcome to 5 Things PM! The US Food and Drug Administration is conducting the first comprehensive update and review of infant formula since 1998. 'We're going to make American infant formula the gold standard for the world,' Health and Human Services Secretary Robert F. Kennedy Jr. said. Here's what else you might have missed during your busy day: 1️⃣ 'We need to change': With President Donald Trump enacting tariffs on nearly every US import, American companies are scrambling to move their supply chains out of countries like Mexico and China. This small island in the Caribbean could be the answer. 2️⃣ Builders of peace: Congregation Bonai Shalom in Boulder, Colorado, welcomes both Jews and non-Jews to participate in all aspects of the community. An antisemitic attack that injured several members — including a Holocaust survivor — is testing their resilience. 3️⃣ Tracking measles: As cases rise to precipitously high levels in the US, there's a new tool to help measure the spread of the disease. Wastewater surveillance has the potential to identify possible cases days before an individual shows symptoms or seeks care. 4️⃣ Lunar lander: A Japanese company will try to touch down on the moon three months after an uncrewed American spacecraft did the same. Ispace executives said their slow and steady approach offers some long-term advantages. 5️⃣ Candid confession: Kylie Jenner detailed her breast augmentation on TikTok — down to the exact size. Her revelation chips away at a taboo. But is it a victory for transparency or a setback for beauty standards? GET '5 THINGS' IN YOUR INBOX CNN's 5 Things newsletter is your one-stop shop for the latest headlines and fascinating stories to start and end your busy day. Sign up here. ☔ Waterlogged: Flash flood emergencies were declared in Wichita and El Dorado, Kansas, after a month's worth of rain fell in one day. The heavy rain flooded roads and submerged cars. • Trump says Putin told him in phone call he will respond to Ukraine's weekend drone attacks• 2 Chinese researchers charged with smuggling biological pathogen to study at university lab• US Education Department threatens Columbia University's accreditation over campus antisemitism concerns 💸 That's how much House Republicans' sweeping tax and spending cuts package would add to the deficit over the next decade, according to a Congressional Budget Office analysis. 🪨 Preserving history: Stephen Townley Bassett is painstakingly recreating mysterious ancient rock art in South Africa before it's lost. His works are no ordinary replicas. I'm not going to be a part of Trump's lying. Pam Hemphill 💬 No thanks: Formerly known as 'MAGA Granny,' Hemphill is a convicted January 6 rioter who served two months in federal prison. Watch as she explains why she refused a pardon from President Trump. 🪖 Approximately how many Russian soldiers have been killed or injured in the war with Ukraine?A. 100,000B. 300,000C. 600,000D. 950,000⬇️ Scroll down for the answer. 🎾 C'est magnifique! Heavy underdog Lois Boisson continued her fairy tale run at the French Open tennis tournament by beating No. 6 seed Mirra Andreeva to advance to the semifinals. The hometown hero's next opponent? American Coco Gauff. 👋 We'll see you tomorrow.🧠 Quiz answer: D. Russia is nearing 1 million war casualties in Ukraine.📧 Check out all of CNN's newsletters. 5 Things PM is produced by CNN's Chris Good, Meghan Pryce, Kimberly Richardson and Morgan Severson.
